Inolimomab in Graft-Versus-Host Disease Therapy
The realm of transplantation medicine faces a persistent challenge: graft-versus-host disease (GVHD). This complication arises when donor cells attack the recipient’s body. Treatment strategies have evolved, and inolimomab has emerged as a pivotal agent in mitigating GVHD. As an anti-CD25 monoclonal antibody, it inhibits interleukin-2 receptor activation. This process suppresses T-cell proliferation, crucial in GVHD […]